132 results on '"Yoshihide Ueda"'
Search Results
2. Cerebral hemorrhage during systemic chemotherapy with atezolizumab and bevacizumab for hepatocellular carcinoma
- Author
-
Eiichiro Yasutomi, Yoshihiko Yano, Atsushi Yamamoto, Jun Kitadai, Naoki Asaji, Ryutaro Yoshida, Yuri Hatazawa, Takanori Matsuura, Yuuki Shiomi, Yoshihide Ueda, and Yuzo Kodama
- Subjects
Hepatology - Published
- 2022
3. Data from Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization
- Author
-
Hiroshi Seno, Hiroyuki Marusawa, Seishi Ogawa, Kazutaka Obama, Shin'ichi Miyamoto, Yoshihide Ueda, Ken Takahashi, Yuji Eso, Mitsuhiro Nikaido, Eriko Iguchi, Takahiko Ito, Mari Teramura, Aya Mizuguchi, Haruhiko Takeda, Tomonori Hirano, Yasuhide Takeuchi, Nobuyuki Kakiuchi, Atsushi Takai, Takahiro Shimizu, and Ken Kumagai
- Abstract
Intestinal metaplasia (IM) is a risk factor for gastric cancer following infection with Helicobacter pylori. To explore the susceptibility of pure gastric IM to cancer development, we investigated genetic alterations in single IM gastric glands. We isolated 50 single IM or non-IM glands from the inflamed gastric mucosa of 11 patients with intramucosal gastric carcinoma (IGC) and 4 patients without IGC; 19 single glands in the noninflamed gastric mucosa of 11 individuals from our cohort and previous dataset were also included as controls. Whole-exome sequencing of single glands revealed significantly higher accumulation of somatic mutations in various genes within IM glands compared with non-IM glands. Clonal ordering analysis showed that IM glands expanded to form clusters with shared mutations. In addition, targeted-capture deep sequencing and copy number (CN) analyses were performed in 96 clustered IM or non-IM gastric glands from 26 patients with IGC. CN analyses were also performed on 41 IGC samples and The Cancer Genome Atlas-Stomach Adenocarcinoma datasets. These analyses revealed that polyclonally expanded IM commonly acquired CN aberrations (CNA), including amplification of chromosomes 8, 20, and 2. A large portion of clustered IM glands typically consisted of common CNAs rather than other cancer-related mutations. Moreover, the CNA patterns of clustered IM glands were similar to those of IGC, indicative of precancerous conditions. Taken together, these findings suggest that, in the gastric mucosa inflamed with H. pylori infection, IM glands expand via acquisition of CNAs comparable with those of IGC, contributing to field cancerization.Significance:This study contributes to our understanding of gastric intestinal metaplasia as a risk factor for gastric adenocarcinoma via their multifocal expansion and acquisition of CNAs and somatic mutations.
- Published
- 2023
4. Supplementary Data from Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization
- Author
-
Hiroshi Seno, Hiroyuki Marusawa, Seishi Ogawa, Kazutaka Obama, Shin'ichi Miyamoto, Yoshihide Ueda, Ken Takahashi, Yuji Eso, Mitsuhiro Nikaido, Eriko Iguchi, Takahiko Ito, Mari Teramura, Aya Mizuguchi, Haruhiko Takeda, Tomonori Hirano, Yasuhide Takeuchi, Nobuyuki Kakiuchi, Atsushi Takai, Takahiro Shimizu, and Ken Kumagai
- Abstract
Supplementary Data from Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization
- Published
- 2023
5. Supplementary Table from Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization
- Author
-
Hiroshi Seno, Hiroyuki Marusawa, Seishi Ogawa, Kazutaka Obama, Shin'ichi Miyamoto, Yoshihide Ueda, Ken Takahashi, Yuji Eso, Mitsuhiro Nikaido, Eriko Iguchi, Takahiko Ito, Mari Teramura, Aya Mizuguchi, Haruhiko Takeda, Tomonori Hirano, Yasuhide Takeuchi, Nobuyuki Kakiuchi, Atsushi Takai, Takahiro Shimizu, and Ken Kumagai
- Abstract
Supplementary Table from Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization
- Published
- 2023
6. Acid‐treated high‐amylose corn starch suppresses high‐fat diet‐induced steatosis
- Author
-
Ryutaro Yoshida, Yoshihiko Yano, Namiko Hoshi, Norihiro Okamoto, Yunlong Sui, Atsushi Yamamoto, Naoki Asaji, Yuuki Shiomi, Eiichiro Yasutomi, Yuri Hatazawa, Hiroki Hayashi, Yoshihide Ueda, and Yuzo Kodama
- Subjects
Male ,high fat diet ,Resistant Starch ,Starch ,SCFA ,Diet, High-Fat ,Fatty Acids, Volatile ,Zea mays ,RS4 ,Fatty Liver ,Mice ,steatosis ,microbiota ,Animals ,Amylose ,Bifidobacterium ,Food Science - Abstract
Resistant starch (RS) has been reported to improve steatosis as well as obesity. Type 4 resistant starch (RS4), a chemically modified starch, is particularly hard to digest and suggesting higher efficacy. However, because the effects of RS4 on steatosis are not yet fully understood, the effects of RS4 on steatosis were examined using a murine high-fat diet model. Seven-week-old male mice were divided into three groups and fed a normal diet, a high-fat diet (HFD), or a high-fat diet with added RS (HFD + RS). Amylofiber SH® produced from acid-treated corn starch was used as the dietary RS. At 22 weeks old, hepatic steatosis and short chain fatty acid (SCFA) content and gut microbiota in cecum stool samples were analyzed. The ratio of body weight to 7 weeks was significantly suppressed in the HFD + RS group compared to the HFD group (132.2 ± 1.4% vs. 167.2 ± 3.9%, p = 0.0076). Macroscopic and microscopic steatosis was also suppressed in the HFD + RS group. Analysis of cecum stool samples revealed elevated SCFA levels in the HFD + RS group compared with the HFD group. Metagenome analysis revealed that Bifidobacterium (17.9 ± 1.9% vs. 3.6 ± 0.7%, p = 0.0019) and Lactobacillus (14.8 ± 3.4% vs. 0.72 ± 0.23%, p = 0.0045), which degrade RS to SCFA, were more prevalent in the HFD + RS group than the HFD group. In conclusion, RS4 suppressed steatosis, and increased Bifidobacterium and Lactobacillus, and SCFAs. RS4 may prevent steatosis by modulating the intestinal environment.
- Published
- 2022
7. Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization
- Author
-
Ken Kumagai, Takahiro Shimizu, Atsushi Takai, Nobuyuki Kakiuchi, Yasuhide Takeuchi, Tomonori Hirano, Haruhiko Takeda, Aya Mizuguchi, Mari Teramura, Takahiko Ito, Eriko Iguchi, Mitsuhiro Nikaido, Yuji Eso, Ken Takahashi, Yoshihide Ueda, Shin'ichi Miyamoto, Kazutaka Obama, Seishi Ogawa, Hiroyuki Marusawa, and Hiroshi Seno
- Subjects
Metaplasia ,Cancer Research ,DNA Copy Number Variations ,Helicobacter pylori ,Oncology ,Gastric Mucosa ,Stomach Neoplasms ,Humans ,Adenocarcinoma ,Precancerous Conditions ,Helicobacter Infections - Abstract
Intestinal metaplasia (IM) is a risk factor for gastric cancer following infection with Helicobacter pylori. To explore the susceptibility of pure gastric IM to cancer development, we investigated genetic alterations in single IM gastric glands. We isolated 50 single IM or non-IM glands from the inflamed gastric mucosa of 11 patients with intramucosal gastric carcinoma (IGC) and 4 patients without IGC; 19 single glands in the noninflamed gastric mucosa of 11 individuals from our cohort and previous dataset were also included as controls. Whole-exome sequencing of single glands revealed significantly higher accumulation of somatic mutations in various genes within IM glands compared with non-IM glands. Clonal ordering analysis showed that IM glands expanded to form clusters with shared mutations. In addition, targeted-capture deep sequencing and copy number (CN) analyses were performed in 96 clustered IM or non-IM gastric glands from 26 patients with IGC. CN analyses were also performed on 41 IGC samples and The Cancer Genome Atlas-Stomach Adenocarcinoma datasets. These analyses revealed that polyclonally expanded IM commonly acquired CN aberrations (CNA), including amplification of chromosomes 8, 20, and 2. A large portion of clustered IM glands typically consisted of common CNAs rather than other cancer-related mutations. Moreover, the CNA patterns of clustered IM glands were similar to those of IGC, indicative of precancerous conditions. Taken together, these findings suggest that, in the gastric mucosa inflamed with H. pylori infection, IM glands expand via acquisition of CNAs comparable with those of IGC, contributing to field cancerization. Significance: This study contributes to our understanding of gastric intestinal metaplasia as a risk factor for gastric adenocarcinoma via their multifocal expansion and acquisition of CNAs and somatic mutations.
- Published
- 2022
8. Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma
- Author
-
SHOHEI KOMATSU, YOSHIHIKO YANO, MASAHIRO KIDO, KAORI KURAMITSU, HIDETOSHI GON, KENJI FUKUSHIMA, TAKESHI URADE, SHINICHI SO, ATSUSHI YAMAMOTO, TADAHIRO GOTO, HIROAKI YANAGIMOTO, HIROCHIKA TOYAMA, YOSHIHIDE UEDA, YUZO KODAMA, and TAKUMI FUKUMOTO
- Subjects
Bevacizumab ,Cancer Research ,Carcinoma, Hepatocellular ,Oncology ,Albumins ,Liver Neoplasms ,Humans ,Bilirubin ,General Medicine ,alpha-Fetoproteins - Abstract
Atezolizumab plus bevacizumab and lenvatinib are the key drugs in the current systemic chemotherapeutic regimen for hepatocellular carcinoma (HCC). Studies have reported the potential effectiveness of lenvatinib introduction after an atezolizumab plus bevacizumab treatment; however, the therapeutic effectiveness of a lenvatinib rechallenge after an atezolizumab plus bevacizumab treatment remains unclear.Thirteen consecutive patients who were rechallenged with lenvatinib after clinical failure following treatments with lenvatinib and atezolizumab plus bevacizumab were included. A comparative study was conducted on the duration and treatment efficacy of the first and second lenvatinib treatments and on the pre- and post-treatment liver function.The median ratios of the 1-month post-treatment alpha-fetoprotein (AFP) levels to the pretreatment AFP levels were 0.750 and 0.667 for the first and second lenvatinib treatments, respectively, without significant difference (p=0.9327). Meanwhile, the median ratios of the 1-month post-treatment albumin-bilirubin (ALBI) scores to the pretreatment ALBI scores were 1.063 and 0.827 for the first and second lenvatinib treatments, respectively, with significant difference (p=0.015). The median duration of the second lenvatinib treatment was significantly shorter than that of the first lenvatinib treatment [2.8 months (range=0.9-4.7 months) vs. 8.7 months (range=3.1-29.7 months)].Lenvatinib re-administration after atezolizumab plus bevacizumab treatment can act as a double-edged sword, as it exerts an anti-tumor effect while being associated with potential liver function deterioration. However, this treatment sequence can be useful, and requires careful monitoring of the transitions in the liver function and the patient's performance status.
- Published
- 2022
9. Evolutional transition of HBV genome during the persistent infection determined by single-molecule real-time sequencing
- Author
-
Soichi Arasawa, Haruhiko Takeda, Atsushi Takai, Eriko Iguchi, Yuji Eso, Takahiro Shimizu, Ken Takahashi, Taiki Yamashita, Yoshihide Ueda, Hiroyuki Marusawa, and Hiroshi Seno
- Subjects
Hepatology - Published
- 2023
10. Health Status of 'Community Cats' Living in the Tourist Area of the Old Town in Onomichi City, Japan
- Author
-
Yoshihide Ueda, Hajime Tanida, and Aira Seo
- Subjects
040301 veterinary sciences ,Anemia ,Health Status ,Cat Diseases ,0403 veterinary science ,Japan ,Control measure ,Zoonoses ,Environmental health ,medicine ,Animals ,Old town ,0501 psychology and cognitive sciences ,050102 behavioral science & comparative psychology ,Cities ,CATS ,Bartonella henselae ,General Veterinary ,biology ,business.industry ,05 social sciences ,04 agricultural and veterinary sciences ,medicine.disease ,biology.organism_classification ,Stray cats ,Cats ,Animal Science and Zoology ,Christian ministry ,business ,Tourism - Abstract
The "community cat program (CCP)" is a non-lethal control measure in which stray cats are owned and cared for as community cats at high welfare standards, while the Trap-Neuter-Return (TNR) or Trap-Test-Vaccinate-Alter-Return-Monitor (TTVARM) event is performed. The program is recommended by the Ministry of the Environment in Japan. Here, we evaluated the health status of community cats inhabiting a tourist area in Onomichi City. A medical check was conducted on 30 community cats as a part of the TTVARM event. The following health problems were identified: alopecia, gingivitis, incisor teeth loss, anemia, and urine glucose. An ELISA (the enzyme linked immunosorbent assay) showed that 16.7% of the cats were FIV-positive. The cats were also carriers of zoonoses (Capnocytophaga genus (100%) and Bartonella henselae (ITS, nested; 38.0%)), which pose a risk to tourists and residents. Our findings suggest that most cats require medical treatment. We recommend that friendly cats should be adopted rather than maintained as community cats and that a comprehensive review of the CCP is required.
- Published
- 2021
11. Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers
- Author
-
Yoshihiko Yano, Hiroki Hayashi, Arata Sakai, Yuuki Shiomi, Eiichiro Yasutomi, Yoshihide Ueda, Kazutoshi Tobimatsu, Yuzo Kodama, Yuri Hatazawa, Ryutaro Yoshida, Naoki Asaji, and Atsushi Yamamoto
- Subjects
Adult ,Male ,0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,genetic structures ,Combination therapy ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Japan ,Risk Factors ,Neoplasms ,Internal medicine ,medicine ,Humans ,Immune Checkpoint Inhibitors ,Aged ,Retrospective Studies ,Aged, 80 and over ,Hematology ,business.industry ,Medical record ,Melanoma ,Cancer ,General Medicine ,Odds ratio ,Middle Aged ,medicine.disease ,Confidence interval ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Elevated transaminases ,Female ,Chemical and Drug Induced Liver Injury ,business - Abstract
The risk factors and clinical characteristics of ICI-induced immune-mediated hepatotoxicity (IMH) are not fully understood. Thus, the present study sought to clarify the clinical features of IMH. All patients treated with ICIs between September 2014 and April 2019 at our institution were included. Clinical data were retrospectively collected from medical records. The frequency of grade ≥ 2 liver damage, clinical characteristics, and risk factors for developing IMH were examined. Overall, 250 patients (median age 71 years; range 30–87 years; 202 males and 48 females) were included in the analyses. Forty-five patients had elevated transaminase levels (> threefold the upper limit of normal). Of these, 21 were considered to have IMH. The remaining 24 patients had other causes of elevated transaminase levels. Steroids were administered to 13/21 patients with IMH. Although all patients exhibited improvement, IMH was not associated with the anticancer efficacy of the ICIs or OS. A multivariable analysis revealed that IMH was significantly associated with malignant melanoma (odds ratio [OR] 11.6; 95% confidence interval [CI] 3.5–38.0; P = 0.0002) and ipilimumab–nivolumab combination therapy (OR 61.2; 95% CI 7.9–1275.3; P
- Published
- 2020
12. Allograft liver failure awaiting liver transplantation in Japan
- Author
-
Takuya Genda, Takafumi Ichida, Eiji Tanaka, Satoshi Mochida, Yoshiyuki Ueno, Shuji Terai, Ayano Inui, Yoshihide Ueda, Hideki Ohdan, Hiroto Egawa, Koji Umeshita, Hiroyuki Furukawa, and Yukihiro Inomata
- Subjects
Adult ,End Stage Liver Disease ,Japan ,Cytidine Triphosphate ,Gastroenterology ,Humans ,Hepacivirus ,Hepatitis C, Chronic ,Allografts ,Hepatitis C ,Liver Transplantation ,Retrospective Studies - Abstract
Following liver transplantation (LT), allograft liver failure can be developed by various causes and requires re-LT. Hence, this study aimed to clarify the characteristics and prognostic factors of patients with allograft liver failure awaiting deceased donor LT (DDLT) in Japan.Of the 2686 DDLT candidates in Japan between 2007 and 2016, 192 adult patients listed for re-LT were retrospectively enrolled in this study. Factors associated with waitlist mortality were assessed using the Cox proportional hazards model. The transplant-free survival probabilities were evaluated using the Kaplan-Meier analysis and log-rank test.The median period from the previous LT to listing for re-LT was 1548 days (range, 4-8449 days). Primary sclerosing cholangitis (PSC), which was a primary indication, showed a higher listing probability for re-LT as compared with other primary etiologies. Recurrent liver disease was a leading cause of allograft failure and was more frequently observed in the primary indication of hepatitis C virus (HCV) infection and PSC in contrast with other etiologies. Multivariate analysis identified the following independent risk factors associated with waitlist mortality: age, Child-Turcotte-Pugh (CTP) score, mode for end-stage liver disease (MELD) score, alanine aminotransferase (ALT), and causes of allograft failure.Recurrent HCV and PSC were major causes of allograft liver failure in Japan. In addition to CTP and MELD scores, either serum ALT levels or causes of allograft failure should be considered as graft liver allocation measures.
- Published
- 2022
13. Use of Nakanuma staging and cytokeratin 7 staining for diagnosing recurrent primary biliary cholangitis after living‐donor liver transplantation
- Author
-
Hironori Haga, Shinji Uemoto, Takashi Ito, Toshimi Kaido, Noriyo Yamashiki, Akira Mori, Yoshihide Ueda, Hideaki Okajima, Shintaro Yagi, Koichiro Hata, and Naoko Kamo
- Subjects
Hepatitis ,medicine.medical_specialty ,Hepatology ,medicine.diagnostic_test ,Bile duct ,business.industry ,medicine.disease ,Gastroenterology ,03 medical and health sciences ,Cytokeratin ,0302 clinical medicine ,Infectious Diseases ,medicine.anatomical_structure ,Fibrosis ,Median follow-up ,030220 oncology & carcinogenesis ,Liver biopsy ,Internal medicine ,Biopsy ,medicine ,030211 gastroenterology & hepatology ,Stage (cooking) ,business - Abstract
AIM Diagnosis of primary biliary cholangitis (PBC), which recurs in approximately 30% of liver transplant recipients, is histology-based, but no staging system has been established for recurrent PBC (rPBC). We used the Nakanuma staging system and cytokeratin 7 (CK7) staining to examine post-transplant liver biopsy specimens retrospectively and to evaluate histological features of rPBC. METHODS From 107 patients who underwent living donor liver transplantation for PBC, 60 recipients with 214 liver biopsies after 1-year post transplant were enrolled. Fibrosis, bile duct loss (BL), cholangitis activity, hepatitis activity, and CK7-positive hepatocytes were scored. Nakanuma staging was based on fibrosis and BL scores. We examined the correlation of scores and clinicolaboratory data among rPBC patients. We also evaluated whether chronological change of stage was correlated with liver-related failure. RESULTS Of 214 biopsies, 52 were protocol biopsy; 162 were episodic. Higher BL, cholangitis activity, and hepatitis activity scores were associated with rPBC diagnosis. At median follow up of 10.0 years (range 1.4-18.7 years), 29 (48%) patients were diagnosed with rPBC at 4.6 years (range 1.3-14.5 years). Liver-related failure occurred in five rPBC cases; three from rPBC, and two from chronic rejection. At rPBC diagnosis, higher BL and CK7 scores were more frequent in patients who developed liver-related failure than in other patients (P = 0.04, P
- Published
- 2020
14. ASO Visual Abstract: Comprehensive Analysis of Molecular Biological Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm
- Author
-
Masahiro Tsujimae, Atsuhiro Masuda, Takuya Ikegawa, Takeshi Tanaka, Jun Inoue, Hirochika Toyama, Keitaro Sofue, Hisahiro Uemura, Shinya Kohashi, Noriko Inomata, Kae Nagao, Shigeto Masuda, Shohei Abe, Masanori Gonda, Kohei Yamakawa, Shigeto Ashina, Yasutaka Yamada, Shunta Tanaka, Ryota Nakano, Arata Sakai, Takashi Kobayashi, Hideyuki Shiomi, Maki Kanzawa, Tomoo Itoh, Takumi Fukumoto, Yoshihide Ueda, and Yuzo Kodama
- Subjects
Oncology ,Surgery - Published
- 2022
15. Exploring the hepatitis C virus genome using single molecule real-time sequencing
- Author
-
Yoshihide Ueda, Akihiro Sekine, Taiki Yamashita, and Haruhiko Takeda
- Subjects
Genome, Viral ,Hepacivirus ,Computational biology ,Biology ,Antiviral Agents ,Genome ,Deep sequencing ,03 medical and health sciences ,0302 clinical medicine ,Drug Resistance, Multiple, Viral ,Nanopore sequencer ,Humans ,Resistance-associated substitution ,Gene ,Sequence (medicine) ,Whole genome sequencing ,Hepatitis C virus ,Haplotype ,Gastroenterology ,High-Throughput Nucleotide Sequencing ,Minireviews ,PacBio RSII ,General Medicine ,Hepatitis C ,Single molecule real-time sequencing ,030220 oncology & carcinogenesis ,RNA, Viral ,030211 gastroenterology & hepatology ,Nanopore sequencing ,Third generation sequencing ,Single molecule real time sequencing - Abstract
Single molecular real-time (SMRT) sequencing, also called third-generation sequencing, is a novel sequencing technique capable of generating extremely long contiguous sequence reads. While conventional short-read sequencing cannot evaluate the linkage of nucleotide substitutions distant from one another, SMRT sequencing can directly demonstrate linkage of nucleotide changes over a span of more than 20 kbp, and thus can be applied to directly examine the haplotypes of viruses or bacteria whose genome structures are changing in real time. In addition, an error correction method (circular consensus sequencing) has been established and repeated sequencing of a single-molecule DNA template can result in extremely high accuracy. The advantages of long read sequencing enable accurate determination of the haplotypes of individual viral clones. SMRT sequencing has been applied in various studies of viral genomes including determination of the full-length contiguous genome sequence of hepatitis C virus (HCV), targeted deep sequencing of the HCV NS5A gene, and assessment of heterogeneity among viral populations. Recently, the emergence of multi-drug resistant HCV viruses has become a significant clinical issue and has been also demonstrated using SMRT sequencing. In this review, we introduce the novel third-generation PacBio RSII/Sequel systems, compare them with conventional next-generation sequencers, and summarize previous studies in which SMRT sequencing technology has been applied for HCV genome analysis. We also refer to another long-read sequencing platform, nanopore sequencing technology, and discuss the advantages, limitations and future perspectives in using these third-generation sequencers for HCV genome analysis.
- Published
- 2019
16. Population Dynamics of Community Cats Living in a Tourist Area of Onomichi City, Japan, before and after the Trap-Test-Vaccinate-Alter-Return-Monitor Event
- Author
-
Hajime Tanida, Yoshihide Ueda, and Aira Seo
- Subjects
education.field_of_study ,General Veterinary ,040301 veterinary sciences ,media_common.quotation_subject ,05 social sciences ,Population ,04 agricultural and veterinary sciences ,Test (assessment) ,0403 veterinary science ,Trap (computing) ,Geography ,Control measure ,parasitic diseases ,0501 psychology and cognitive sciences ,Animal Science and Zoology ,Christian ministry ,050102 behavioral science & comparative psychology ,Socioeconomics ,education ,Welfare ,Tourism ,media_common - Abstract
The community cat program (CCP) was recommended by the Ministry of the Environment to reduce cats in local animal shelters and improve stray cat welfare in Japan. It is a non-lethal control measure with stray cats cared for as free-roaming cats for their lifetime in the community, while Trap-Neuter-Return (TNR) or Trap-Test-Vaccinate-Alter-Return-Monitor (TTVARM) activities are carried out. In the CCP, community cat colonies are hypothesized to be closed and static populations. However, it remains unknown whether the cats stay in the colonies, without migration of non-neutered cats following TNR/TTVARM events. We examined the population dynamics of cats before and after a TTVARM event using route censuses (107 days), fixed-point observations, and GPS-tracking in a tourist area in Onomichi. Eleven out of the 30 cats remained in the CCP areas, whereas 13 non-neutered cats immigrated into the CCP areas, within a year, suggesting the CCP program has limited efficacy. Besides, the program cannot support the lifetime management of the cats due rapid turnover of cats. Our results reject the CCP hypothesis, so that the program neither restricts cat breeding nor enhances cat welfare.
- Published
- 2021
17. Oncogenic transcriptomic profile is sustained in the liver after the eradication of the hepatitis C virus
- Author
-
Eriko Iguchi, Ken Kumagai, Hiroyuki Marusawa, Hiroko Iijima, Soichi Arasawa, Kojiro Taura, Etsuro Hatano, Yuji Eso, Atsushi Takai, Masako Mishima, Hiroshi Seno, Haruhiko Takeda, Takaji Wakita, Takahiro Shimizu, Yoshihide Ueda, Haruyo Aoyagi, Ken Takahashi, and Hideki Aizaki
- Subjects
0301 basic medicine ,Liver Cirrhosis ,Male ,Cancer Research ,Carcinoma, Hepatocellular ,Sustained Virologic Response ,Carcinogenesis ,Hepatitis C virus ,Hepacivirus ,medicine.disease_cause ,Transcriptome ,03 medical and health sciences ,0302 clinical medicine ,Cell Line, Tumor ,Databases, Genetic ,medicine ,Humans ,RNA-Seq ,business.industry ,Liver Neoplasms ,virus diseases ,Cancer ,General Medicine ,Hepatitis C ,medicine.disease ,digestive system diseases ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,Liver ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Cancer research ,Biomarker (medicine) ,Female ,business ,Liver cancer ,Cysteine-Rich Protein 61 - Abstract
Hepatocellular carcinoma (HCC) developing after hepatitis C virus (HCV) eradication is a serious clinical concern. However, molecular basis for the hepatocarcinogenesis after sustained virologic response (SVR) remains unclear. In this study, we aimed to unveil the transcriptomic profile of post-SVR liver tissues and explore the molecules associated with post-SVR carcinogenesis. We analysed 90 RNA sequencing datasets, consisting of non-cancerous liver tissues including 20 post-SVR, 40 HCV-positive and 7 normal livers, along with Huh7 cell line specimens before and after HCV infection and eradication. Comparative analysis demonstrated that cell cycle- and mitochondrial function-associated pathways were altered only in HCV-positive non-cancerous liver tissues, whereas some cancer-related pathways were up-regulated in the non-cancerous liver tissues of both post-SVR and HCV-positive cases. The persistent up-regulation of carcinogenesis-associated gene clusters after viral clearance was reconfirmed through in vitro experiments, of which, CYR61, associated with liver fibrosis and carcinogenesis in several cancer types, was the top enriched gene and co-expressed with cell proliferation-associated gene modules. To evaluate whether this molecule could be a predictor of hepatocarcinogenesis after cure of HCV infection, we also examined 127 sera from independent HCV-positive cohorts treated with direct-acting antivirals (DAAs), including 60 post-SVR-HCC patients, and found that the elevated serum Cyr61 was significantly associated with early carcinogenesis after receiving DAA therapy. In conclusion, some oncogenic transcriptomic profiles are sustained in liver tissues after HCV eradication, which might be a molecular basis for the liver cancer development even after viral clearance. Among them, up-regulated CYR61 could be a possible biomarker for post-SVR-HCC.
- Published
- 2020
18. Jejunal variceal rupture in a patient with myelofibrosis: a case report
- Author
-
Yoshihide Ueda, Tomonori Wada, Eiichiro Yasutomi, Yuri Hatazawa, Kimihiro Yamashita, Yuuki Shiomi, Yoshihiko Yano, Masato Kinoshita, Atsushi Yamamoto, Hiroki Hayashi, and Yuzo Kodama
- Subjects
Male ,medicine.medical_specialty ,Gastrointestinal bleeding ,Anemia ,Varicose Veins ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Hypertension, Portal ,Medicine ,Humans ,Myelofibrosis ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Gastroenterology ,General Medicine ,Hepatology ,medicine.disease ,Surgery ,Endoscopy ,Jejunum ,Primary Myelofibrosis ,030220 oncology & carcinogenesis ,Portal hypertension ,030211 gastroenterology & hepatology ,Segmental resection ,business ,Gastrointestinal Hemorrhage ,Abdominal surgery - Abstract
An 80-year old man with myelofibrosis and chronic renal disease was admitted to our hospital because of severe anemia and gastrointestinal bleeding. Although no bleeding was observed by upper or lower endoscopy, contrast-enhanced computed tomography revealed an enhanced area in the small intestinal wall that was suspected of being the bleeding site, and was confirmed by double-balloon endoscopy. Based on endoscopic findings, it was difficult to differentiate between variceal rupture and collapse of a submucosal tumor. We performed segmental resection of the small intestine to make a definitive diagnosis and achieve reliable hemostasis. The gross findings confirmed a variceal rupture from the small intestine. His gastrointestinal bleeding stopped and his anemia improved following surgery. Although some cases of portal hypertension in association with myelofibrosis have been reported, we are aware of no prior reports of variceal rupture in the small intestine. To our knowledge, this is the first reported case of ectopic jejunal varices in a patient with myelofibrosis.
- Published
- 2020
19. Beta-catenin-activated hepatocellular adenoma in a male
- Author
-
Yuri Hatazawa, Yoshihiko Yano, Tomoo Itoh, Eiichiro Yasutomi, Yuuki Shiomi, Hidetoshi Gon, Maki Kanzawa, Ryosuke Ishida, Hiroki Hayashi, Yoshihide Ueda, Atsushi Yamamoto, Yuzo Kodama, and Satoshi Omiya
- Subjects
Male ,medicine.medical_specialty ,Pathology ,Liver tumor ,Carcinoma, Hepatocellular ,Malignant transformation ,Adenoma, Liver Cell ,03 medical and health sciences ,0302 clinical medicine ,Surgical oncology ,Internal medicine ,medicine ,Hepatectomy ,Humans ,beta Catenin ,medicine.diagnostic_test ,business.industry ,Liver Neoplasms ,Gastroenterology ,Magnetic resonance imaging ,General Medicine ,Hepatocellular adenoma ,Hepatology ,Middle Aged ,medicine.disease ,Hyperintensity ,030220 oncology & carcinogenesis ,Immunohistochemistry ,030211 gastroenterology & hepatology ,business - Abstract
Beta-catenin-activated hepatocellular adenoma is potentially malignant and warrants careful follow-up and surgical resection. Here, we report a 48-year-old man in whom a 55 mm single liver tumor was incidentally detected in the S1 segment. Contrast-enhanced computed tomography scans showed no enhancement in the early phase and a slight defection in the late phase. The tumor was enhanced hyperintensity in the hepatobiliary phase on Gd-ethoxybenzyl-diethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging. The histologic features of ultrasound-guided fine-needle aspiration biopsy indicated hepatocellular adenoma, and the tumor was immunohistochemically positive for glutamine synthetase and β-catenin. Considering the risk of malignant transformation, he underwent laparoscopic-assisted partial liver resection. The resected tumor did not contain any malignant lesions. This case indicates that aspiration needle biopsy and immunohistochemistry were useful for histological diagnosis and treatment decisions based on the molecular definition of hepatocellular adenoma.
- Published
- 2020
20. Liver abscess caused by Cutibacterium namnetense after transarterial chemoembolization for hepatocellular carcinoma
- Author
-
Ryutaro Yoshida, Naoki Asaji, Yuuki Shiomi, Yoshihide Ueda, Eiichiro Yasutomi, Yuzo Kodama, Hiroki Hayashi, Yuri Hatazawa, Atsushi Yamamoto, and Yoshihiko Yano
- Subjects
Male ,medicine.medical_specialty ,Abdominal pain ,Percutaneous ,Carcinoma, Hepatocellular ,Liver Abscess ,Gastroenterology ,Transarterial chemoembolization ,Lesion ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,Humans ,Chemoembolization, Therapeutic ,Abscess ,Aged ,Retrospective Studies ,business.industry ,Liver Neoplasms ,General Medicine ,Hepatology ,Propionibacteriaceae ,medicine.disease ,Treatment Outcome ,Cutibacterium namnetense ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,030211 gastroenterology & hepatology ,medicine.symptom ,business ,Abdominal surgery ,Liver abscess - Abstract
A 72-year-old man underwent transarterial chemoembolization (TACE) for solitary hepatocellular carcinoma (HCC) located on the S6 segment. He had a history of anti-viral therapy for hepatitis C virus and was being treated for diabetes mellitus with inadequate control. On day 28 after TACE, he visited our hospital again, with complaints of fever and abdominal pain in the right upper quadrant. Blood examination showed elevated levels of white blood cells and C-reactive protein. Computed tomography showed a poorly marginated, low-density lesion measuring 9.5 x 8.0 x 4.0 cm, forming multiple small gas bubbles, located superiorly, and in contact with HCC treated by TACE. Ultrasound-guided puncture revealed whiffy and muddy pus. Gram staining of the pus showed the presence of numerous gram-positive rods, which were identified as Cutibacterium namnetense. He underwent percutaneous trans-hepatic abscess drainage and received antibiotics treatment. The abscess was successfully treated, and he was discharged on day 19. The incidence of liver abscess after TACE is rare, and intestinal microbiota have been reported to be the common pathogens. To the best of our knowledge, this is the first case of liver abscess caused by Cutibacterium namnetense.
- Published
- 2020
21. Multiregional whole-genome sequencing of hepatocellular carcinoma with nodule-in-nodule appearance reveals stepwise cancer evolution
- Author
-
Eriko Iguchi, Soichi Arasawa, Kojiro Taura, Hironori Haga, Atsushi Takai, Hiroyuki Marusawa, Yoshihide Ueda, Ken Kumagai, Hiroshi Seno, Haruhiko Takeda, Shinji Uemoto, Yuji Eso, Akihiro Fujimoto, Ryuichi Kita, and Takahiro Shimizu
- Subjects
0301 basic medicine ,Male ,Carcinoma, Hepatocellular ,DNA Copy Number Variations ,Carcinogenesis ,Biology ,Pathology and Forensic Medicine ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Biomarkers, Tumor ,Early Hepatocellular Carcinoma ,Humans ,Telomerase reverse transcriptase ,Promoter Regions, Genetic ,Genetic testing ,Aged ,Cell Proliferation ,Chromothripsis ,medicine.diagnostic_test ,Whole Genome Sequencing ,Genetic heterogeneity ,Point mutation ,Liver Neoplasms ,HCCS ,Middle Aged ,medicine.disease ,digestive system diseases ,030104 developmental biology ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Mutation ,Cancer research ,Disease Progression ,Female - Abstract
Recent genetic analyses revealed genetic heterogeneity in hepatocellular carcinoma (HCC), although it remains unclear how genetic alterations contribute to the multistage progression of HCC, especially the early step from hypovascular liver nodules to hypervascular HCC. We conducted multiregional whole-genome sequencing on HCCs with a nodule-in-nodule appearance, consisting of inner hypervascular HCC surrounded by hypovascular HCC arising from a common origin, and identified point mutations, structural variations, and copy-number variations in each specimen. According to the genetic landscape of the inner and outer regions, together with the pathological and radiological findings, we examined the stepwise evolution of cancer cells from slow-growing HCC to rapid-growing HCC. We first demonstrated that most tumor cells consisting of hypovascular well-differentiated HCCs already harbored thousands of point mutations and even several structural variations, including chromosomal translocations and chromothripsis, as the trunk events. Telomerase reverse transcriptase (TERT)-associated aberrations, including promoter mutations, chromosomal translocation, and hepatitis B virus DNA integration, as well as abnormal methylation status, were commonly detected as the trunk aberrations, while various liver cancer-related genes, which differed in each case, had additionally accumulated in the inner dedifferentiated nodules. Further, differences in the trunk and branch mutational signatures suggested a multistep contribution to the mutagenesis in each case. In conclusion, genomic alterations associated with the TERT gene could be the key driver events to form the hypovascular HCC, and additional case-specific driver mutations accumulate during the progression phase, forming intra- and inter-tumoral heterogeneity, confirming the importance of genetic testing before targeting therapy. These data shed light on the process of multistep hepatocarcinogenesis and will be helpful toward investigating new therapeutic strategies for HCC. © 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- Published
- 2020
22. Portal vein thrombosis due to essential thrombocythemia with limited cutaneous systemic sclerosis
- Author
-
Ken Takahashi, Syoko Narukami, Yoshihide Ueda, Kenji Sawada, Masahiro Shiokawa, Kentaro Iwaki, Junya Kanda, Masako Mishima, and Hiroshi Seno
- Subjects
medicine.medical_specialty ,Cirrhosis ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Myeloproliferative Disorders ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Platelet ,Scleroderma, Systemic ,Thrombocytosis ,Essential thrombocythemia ,business.industry ,Portal Vein ,Liver Diseases ,Thrombosis ,General Medicine ,Hepatology ,Middle Aged ,medicine.disease ,Portal vein thrombosis ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Female ,Bone marrow ,business ,Thrombocythemia, Essential - Abstract
Portal vein thrombosis is caused by various diseases, including liver cirrhosis, cancer, abdominal infection, and myeloproliferative disorders. Essential thrombocythemia is one of the myeloproliferative disorders in which the bone marrow produces excessive amount of platelets and can be accompanied by various thrombotic diseases; however, essential thrombocythemia with limited cutaneous systemic sclerosis has not been reported yet. We herein report a case of extensive portal vein thrombosis due to essential thrombocythemia with limited cutaneous systemic sclerosis. A 49-year-old woman was referred to our hospital due to liver dysfunction. Extended portal vein thrombosis, splenomegaly, and thrombocytosis were founded. The examination of Janus kinase 2 V617F mutation in the bone marrow was positive. These findings resulted in the diagnosis of portal vein thrombosis due to essential thrombocythemia. Furthermore, Raynaud's phenomenon, finger's sclerosis, and positive anti-centromere antibody led to limited cutaneous systemic sclerosis. To further analyze the causal relationship between essential thrombocythemia and limited cutaneous systemic sclerosis, platelet-derived growth factor was examined. High level of serum platelet-derived growth factor, possibly caused by high platelet count due to essential thrombocythemia, was observed. As platelet-derived growth factor has been reportedly associated with the occurrence of systemic sclerosis, the present case indicates the possible causal link between essential thrombocythemia and limited cutaneous systemic sclerosis through high platelet-derived growth factor.
- Published
- 2020
23. Single-molecular real-time deep sequencing reveals the dynamics of multi-drug resistant haplotypes and structural variations in the hepatitis C virus genome
- Author
-
Soichi Arasawa, Shigeru Ohtsuru, Yoshihide Ueda, Hiroshi Seno, Akihiro Sekine, Haruhiko Takeda, Atsushi Takai, Fumiyasu Nakamura, Taiki Yamashita, Yoichi Mashimo, and Miyuki Hozan
- Subjects
0301 basic medicine ,Nonsynonymous substitution ,Hepatitis C virus ,lcsh:Medicine ,Genomics ,Genome, Viral ,Hepacivirus ,Viral quasispecies ,Biology ,medicine.disease_cause ,Antiviral Agents ,Genome ,Article ,Deep sequencing ,03 medical and health sciences ,0302 clinical medicine ,Drug Resistance, Viral ,medicine ,Humans ,lcsh:Science ,NS5A ,Cancer ,Genetics ,Multidisciplinary ,lcsh:R ,Haplotype ,High-Throughput Nucleotide Sequencing ,Hepatitis C ,Drug Resistance, Multiple ,Single Molecule Imaging ,030104 developmental biology ,Haplotypes ,lcsh:Q ,030211 gastroenterology & hepatology - Abstract
While direct-acting antivirals (DAAs) for hepatitis C virus (HCV) have dramatically progressed, patients still suffer from treatment failures. For the radical eradication of HCV, a deeper understanding of multiple resistance-associated substitutions (RASs) at the single-clone level is essential. To understand HCV quasispecies and their dynamics during DAA treatment, we applied single-molecule real-time (SMRT) deep sequencing on sera from 12 patients with genotype-1b HCV infections with DAA treatment failures, both pre- and post-treatment. We identified >3.2 kbp sequences between NS3 and NS5A genes of 187,539 clones in total, classifying into haplotype codes based on the linkage of seven RAS loci. The number of haplotype codes during the treatment, per sample, significantly decreased from 14.67 ± 9.12 to 6.58 ± 7.1, while the number of nonsynonymous codons on the seven RAS loci, per clone, significantly increased from 1.50 ± 0.92 to 3.64 ± 0.75. In five cases, the minority multi-drug resistant haplotypes at pre-treatment were identical to the major haplotypes at relapse. Moreover, various structural variations (SVs) were detected and their dynamics analysed. These results suggest that SMRT deep sequencing is useful for detecting minority haplotypes and SVs, and to evaluate the dynamics of viral genomes at the single-clone level.
- Published
- 2020
24. Hepatitis-associated Aplastic Anemia with Rapid Progression of Liver Fibrosis Due to Repeated Hepatitis
- Author
-
Ken Takahashi, Yoshihide Ueda, Osamu Araki, Tomoyo Yamada, Yuki Yamauchi, Yuji Eso, Takero Shindo, Hiroshi Seno, Takaki Sakurai, Kenji Sawada, and Atsushi Takai
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Liver fibrosis ,Case Report ,Gastroenterology ,Hepatitis ,Treatment plan ,Internal medicine ,Liver tissue ,hemic and lymphatic diseases ,Internal Medicine ,medicine ,Humans ,hepatitis-associated aplastic anemia ,Aplastic anemia ,Pathological ,liver fibrosis ,business.industry ,Bone marrow failure ,Anemia, Aplastic ,General Medicine ,medicine.disease ,Pancytopenia ,Disease Progression ,business ,Immunosuppressive Agents - Abstract
Hepatitis-associated aplastic anemia (HAAA) is a variant of acquired aplastic anemia and characterized by bone marrow failure that follows the development of acute hepatitis. We herein report a rare case of HAAA with rapid progression of liver fibrosis due to repeated hepatitis. A pathological examination of liver specimens revealed liver fibrosis progression over a short period. Immunosuppressive therapy with cyclosporine effectively cured both the pancytopenia and hepatitis. Our case suggests that the pathological examination of the liver tissue is useful for determining a treatment plan and that immunosuppressive therapy is a promising treatment for both aplastic anemia and persistent hepatitis.
- Published
- 2019
25. Ultrasound-guided microfoam sclerotherapy with polidocanol for symptomatic giant hepatic cyst: Initial experience
- Author
-
Akihiro Furuta, Yuji Eso, Ken Takahashi, Hiroshi Seno, Hiroyuki Marusawa, Yoshihide Ueda, and Atsushi Takai
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,medicine.medical_treatment ,Ultrasound ,medicine.disease ,Ultrasound guided ,030218 nuclear medicine & medical imaging ,Surgery ,Polidocanol ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,parasitic diseases ,medicine ,Sclerotherapy ,030211 gastroenterology & hepatology ,Cyst ,Hepatic Cyst ,Adverse effect ,business ,Liver cysts ,medicine.drug - Abstract
Aim In cases of symptomatic giant hepatic cysts, appropriate treatment is required to relieve symptoms. Ethanol, minocycline hydrochloride, and ethanolamine oleate have been conventionally used for ultrasound (US)-guided sclerotherapy. However, liquid sclerosing agents could mix with the residual fluid in the cyst and reduce their sclerotic effects. We carried out US-guided microfoam sclerotherapy using polidocanol for three patients and evaluated its efficacy and safety. Methods Between May 2016 and March 2017, three female patients with symptomatic giant hepatic cysts were referred to our hospital. All of them were prospectively included in this study. Results The maximum diameters of the hepatic cysts in the three patients were 92 × 89 × 86 mm, 155 × 119 × 140 mm, and 223 × 195 × 123 mm, respectively. Polidocanol microfoam was successfully administered through an 8.5-Fr pigtail catheter for all patients. One, two, and three microfoam sclerotherapy sessions were undertaken according to the initial cyst volume for cases 1, 2, and 3, respectively. The mean reduction rates of the cyst volume were 90.1% (85.5-98.9%) at 3 months, 96.3% (91.9-99.9%) at 6 months, and 99.5% (99.1-99.9%) at 9 months after treatment. No significant treatment-induced adverse effects were observed. Conclusion Ultrasound-guided microfoam sclerotherapy using polidocanol could be an effective and safe method for the treatment of symptomatic giant liver cysts.
- Published
- 2018
26. Impact of Donor Age on Recipient Survival in Adult-to-Adult Living-donor Liver Transplantation
- Author
-
Noriyo Yamashiki, Toshimi Kaido, Hideaki Okajima, Shinji Uemoto, Hirokazu Tanaka, Toyonari Kubota, Shintaro Yagi, Ichiro Tamaki, Jiro Kusakabe, Takayuki Anazawa, Yusuke Okamura, Hirofumi Hirao, Koichiro Hata, Takashi Sozu, Shoichi Kageyama, Yoshihide Ueda, Junichi Yoshikawa, and Atsushi Yoshizawa
- Subjects
Adult ,medicine.medical_specialty ,Multivariate analysis ,medicine.medical_treatment ,030230 surgery ,Liver transplantation ,Gastroenterology ,Donor age ,Nuclear Family ,End Stage Liver Disease ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Living Donors ,medicine ,Humans ,Young adult ,Retrospective Studies ,business.industry ,Graft Survival ,Age Factors ,Retrospective cohort study ,Hepatitis C ,Middle Aged ,medicine.disease ,Liver regeneration ,Liver Transplantation ,030211 gastroenterology & hepatology ,Surgery ,Living donor liver transplantation ,business - Abstract
OBJECTIVE To investigate the influence of donor age on recipient outcome after living-donor partial liver transplantation (LDLT). BACKGROUND Donor age is a well-known prognostic factor in deceased donor liver transplantation; however, its role in LDLT remains unclear. METHODS We retrospectively analyzed 315 consecutive cases of primary adult-to-adult LDLT in our center between April 2006 and March 2014. Recipients were divided into 5 groups according to the donor age: D-20s (n = 60); D-30s (n = 72); D-40s (n = 57); D-50s (n = 94); and D-60s (n = 32). The recipient survival and the association with various clinical factors were investigated. RESULTS Recipient survival proportions were significantly higher in D-20s compared with all the other groups (P = 0.008, < 0.001, < 0.001, and = 0.006, vs D-30s, -40s, -50s, and -60s, respectively), whereas there was no association between recipient survival and their own age. There are 3 typical relationships between donors and recipients in adult-to-adult LDLT: from child-to-parent, between spouses/siblings, and from parent-to-child. The overall survival in child-to-parent was significantly higher than in spouses/siblings (P = 0.002) and in parent-to-child (P = 0.005), despite significantly higher recipient age in child-to-parent [59 (42-69) years, P < 0.001]. Contrastingly, parent-to-child exhibited the lowest survival, despite the youngest recipient age [26 (20-43) years, P < 0.001]. In addition, younger donor age exhibited significantly better recipient survival both in hepatitis C virus-related and in non-hepatitis C virus diseases. Univariate and multivariate analyses both demonstrated that donor age and graft-type (right-sided livers) are independent prognostic factors for recipient survival. CONCLUSIONS Donor age is an independent, strong prognostic factor in adult-to-adult LDLT.
- Published
- 2018
27. Association of Mac-2-binding protein glycosylation isomer level with nutritional status in chronic liver disease
- Author
-
Hiroshi Seno, Yuji Eso, Atsushi Takai, Ken Takahashi, Kojiro Taura, Hiroyuki Marusawa, and Yoshihide Ueda
- Subjects
Hepatitis ,medicine.medical_specialty ,Hepatology ,biology ,business.industry ,Surrogate endpoint ,Hepatitis C virus ,Gastroenterology ,Serum albumin ,medicine.disease_cause ,medicine.disease ,Chronic liver disease ,03 medical and health sciences ,0302 clinical medicine ,Fibrosis ,030220 oncology & carcinogenesis ,Internal medicine ,Hepatocellular carcinoma ,medicine ,biology.protein ,030211 gastroenterology & hepatology ,Hypoalbuminemia ,business - Abstract
BACKGROUND AND AIM Mac-2-binding protein glycosylation isomer (M2BPGi) was recently identified as a serum glycobiomarker for liver fibrosis. However, the relationship between M2BPGi and malnutrition in patients with chronic liver disease (CLD) is unknown. We aimed to evaluate whether M2BPGi could be a surrogate marker for malnutrition in patients with CLD. METHODS In total, 338 outpatients with CLD were enrolled (median age: 67 years). We evaluated the associations among liver fibrosis markers (M2BPGi, fibrosis-4 index, and aspartate aminotransferase-to-platelet count ratio index), Child-Pugh stages, and nutritional status markers. RESULTS The median value (range) of serum M2BPGi levels was 0.94 cut-off index (COI) (0.22-11.57) in chronic hepatitis and Child-Pugh A (n = 274), 4.775 COI (1.32-16.68) in Child-Pugh B (n = 46), and 11.37 COI (6.03-18.33) in Child-Pugh C (n = 18) (overall significance, P
- Published
- 2018
28. Hepatitis B virus genotype E infection among Egyptian health care workers
- Author
-
Mahmoud Haddad Hemidah, Ashraf Elbahrawy, Ahmed Elwassief, Ahmed Alashker, Amr Elmestikawy, Hossam Shahba, Mohamed Ali Abdelbaseer, Hendawy Abd El-Moaty Zedan, Alaa Hashim, Tsutomu Chiba, Abdel-Gawad Saied Mohammad, Gamal El Didamony, Ahmed Gawish, Yoshihide Ueda, Mohamed Morsy, Hafez Abdelhafeez, Mohamed El Fayoumei, Abdallah Mahmoud Abdallah, and Reem Elmaghloub
- Subjects
0301 basic medicine ,HBsAg ,medicine.medical_specialty ,030106 microbiology ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Health care ,Genotype ,Internal Medicine ,medicine ,030212 general & internal medicine ,Hepatitis B virus ,biology ,business.industry ,Transmission (medicine) ,virus diseases ,Hepatitis B ,medicine.disease ,digestive system diseases ,biology.protein ,Original Article ,Antibody ,business ,Nested polymerase chain reaction - Abstract
Background and Objectives Health Care Workers (HCWs) are at a high risk of needle stick injuries and HBV infection in Egypt; this problem is further aggravated by low Hepatitis B (HB) vaccination coverage. Limited data are available on the prevalence of HBV infection in Egyptian HCWs. In this study, we aimed to assess the HBV infection rate and genotypes among Egyptian HCWs. Methods Five hundred and sixty-four (564) HCWs were included. Of them, 258 (45.74%) were health care providers and 306 (54.25%) were non-health care providers. All HCWs completed both the study questionnaires and provided a blood sample for HBV testing. Indeed, all HCWs were tested for Hepatitis B surface antigen (HBsAg) and antibody to Hepatitis B core antigen (anti-HBc), by enzyme-linked immunosorbent assay. HBVDNA was checked for HCWs who tested positive for HBsAg and/or anti-HBc, by nested Polymerase Chain Reaction (PCR). HBVDNA positive HCWs were further subjected to HBV genotyping. Results The mean age of included HCWs was 33.0 ± 9.8 years, of whom 319 (56.56%) were males. The mean duration of health care work was 9.3 ± 6.7 years. The frequency of HBsAg and anti-HBc were 1.4%, and 24.5%, respectively. Old age and prolonged duration of health care work were significantly associated with anti-HBc seropositivity. Among 140 HCWs positive for HBsAg and/or anti-HBc, 14 (10 %) had positive HBVDNA by PCR. HBV/E (n = 7), HBV/D (n = 3) and co-infection with E and D (n = 4) genotypes were detected. Conclusion Egyptian HCWs have a significantly high rate of HBV exposure. The detection of HBV/E genotype among Egyptian HCWs suggests prevalent transmission of HBV/E among Egyptian populations.
- Published
- 2017
29. Two cases of granulomatous hepatitis due to disseminated bacillus Calmette-Guérin (BCG) disease
- Author
-
Hiroshi Seno, Ken Takahashi, Haruhiko Takeda, Soichi Arasawa, Fumiyasu Nakamura, Atsushi Takai, Masako Mishima, Hiroyuki Marusawa, Yoshihide Ueda, and Yuji Eso
- Subjects
03 medical and health sciences ,0302 clinical medicine ,Hepatology ,business.industry ,030220 oncology & carcinogenesis ,030232 urology & nephrology ,Medicine ,business - Published
- 2017
30. The role of hepatologists in liver transplantation; the results of questionnaire survey for institutions belonging to the Japanese Liver Transplantation Society
- Author
-
Eiji Tanaka, Shinji Uemoto, Noriyo Yamashiki, Yoshihide Ueda, Yoshiyuki Ueno, Masatoshi Ishigami, and Hiroyuki Furukawa
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,medicine.medical_treatment ,Questionnaire ,Liver transplantation ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Family medicine ,Internal medicine ,medicine ,030211 gastroenterology & hepatology ,business - Published
- 2017
31. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience
- Author
-
Toru Ikegami, Hiroshi Seno, Mitsuhisa Takatsuki, Nobuhisa Akamatsu, Shugo Mizuno, Yasuhiko Sugawara, Shinji Uemoto, Yoshihiko Maehara, Akinobu Takaki, Tsuyoshi Kobayashi, Masatoshi Ishigami, Yoshihide Ueda, and Satoshi Miuma
- Subjects
Male ,medicine.medical_specialty ,Cirrhosis ,Pyrrolidines ,Genotype ,Sustained Virologic Response ,medicine.medical_treatment ,Hepacivirus ,Liver transplantation ,Gastroenterology ,Antiviral Agents ,Cohort Studies ,Japan ,Recurrence ,Internal medicine ,Quinoxalines ,medicine ,Humans ,Aged ,Sulfonamides ,business.industry ,Hepatitis C ,Glecaprevir ,Jaundice ,Hepatology ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,Pibrentasvir ,Liver Transplantation ,Regimen ,Drug Combinations ,Benzimidazoles ,Female ,medicine.symptom ,business - Abstract
Efficacy of 8-week regimen with direct-acting antivirals (DAA) for patients with hepatitis C after liver transplantation has not been clarified. This study aimed to clarify the efficacy and safety of glecaprevir and pibrentasvir therapy for 8 and 12 weeks in Japanese patients with recurrent hepatitis C after liver transplantation. A cohort study of liver transplant recipients with recurrent hepatitis C treated with glecaprevir (300 mg/day) and pibrentasvir (120 mg/day) was performed at nine liver transplant centers in Japan. Twenty-five patients with hepatitis C after liver transplantation were treated with glecaprevir and pibrentasvir. Twenty-four patients completed the treatment protocol; treatment was discontinued in one patient who had nausea at 3 days after the initiation of treatment. All the 24 patients who completed the 8- or 12-week treatment protocol achieved a sustained virological response 12 weeks after completion of treatment (SVR12). The SVR12 rates in patients with HCV genotype 1 and 2 were 100% (21 of 21 patients) and 75% (3 of 4 patients), respectively. All patients with prior DAA therapy failure (n = 6), jaundice (n = 4), and liver cirrhosis (n = 4) achieved SVR12. Seven of 8 patients (88%) with severe renal impairment achieved SVR12. Adverse events occurred in 6 of 25 patients (24%), including serious adverse events in 2 patients (8%). Treatment-related adverse events were nausea, pruritus, and mild renal dysfunction. Eight- or 12-week regimen of glecaprevir and pibrentasvir is efficacious and safe in patients with recurrent HCV infection after liver transplantation, even in difficult-to-treat populations, including patients with severe renal impairment, prior DAA experience, liver cirrhosis, or jaundice after liver transplantation.
- Published
- 2018
32. Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience
- Author
-
Yuko Kitagawa, Ken Shirabe, Shigeru Marubashi, Shinji Uemoto, Toru Ikegami, Akihiko Soyama, Tomoharu Yoshizumi, Yoshihiko Maehara, Hideaki Okajima, Hiroaki Nagano, Yukihiro Inomata, Hideki Ohdan, Masahiro Shinoda, Nobuhisa Akamatsu, Susumu Eguchi, Norihiro Kokudo, Masaki Honda, Yoshihide Ueda, and Kohei Ishiyama
- Subjects
Simeprevir ,medicine.medical_specialty ,Anemia ,medicine.medical_treatment ,Liver transplantation ,Gastroenterology ,Telaprevir ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Medicine ,Adverse effect ,Hepatology ,business.industry ,Ribavirin ,Hepatitis C ,medicine.disease ,Infectious Diseases ,Tolerability ,chemistry ,030220 oncology & carcinogenesis ,Immunology ,030211 gastroenterology & hepatology ,business ,medicine.drug - Abstract
Aim This study aimed to clarify the efficacy and safety of simeprevir, a second-generation NS3/4A inhibitor, with peginterferon and ribavirin for recurrent hepatitis C after liver transplantation. Methods A retrospective cohort study of living-donor liver transplant recipients with recurrent hepatitis C with the hepatitis C virus genotype 1 treated with either simeprevir- or telaprevir-based triple therapy was carried out at eight Japanese liver transplant centers. Results Simeprevir- and telaprevir-based triple therapies were given to 79 and 36 patients, respectively. Of the 79 patients treated with simeprevir-based triple therapy, 44 (56%) achieved sustained virological response 12 weeks (SVR12) after treatment ended, and there was no significant difference in the SVR12 between the simeprevir- and telaprevir-based triple therapy groups (69%). The rates of adverse events were not significantly different between the simeprevir- and telaprevir-based triple therapy groups, although the rate of patients who received blood cell transfusion and erythropoietin due to anemia and had renal insufficiency were significantly higher in the telaprevir group than in the simeprevir group. Three baseline factors, the presence of prior dual therapy with peginterferon and ribavirin (P = 0.001), a non-responder to the prior dual therapy (P
- Published
- 2016
33. Physiological conditions in iPRECIO® -implanted rats
- Author
-
Yoshihide Ueda, Masaru Tsuboi, Takuya Aoshima, Yasufumi Ota, Fukutaro Mizuhashi, and Hiroshi Takehara
- Subjects
0301 basic medicine ,03 medical and health sciences ,medicine.medical_specialty ,030104 developmental biology ,0302 clinical medicine ,Endocrinology ,business.industry ,Physiological condition ,Internal medicine ,medicine ,Infusion pump ,business ,030226 pharmacology & pharmacy - Published
- 2016
34. Hepatitis C Treatment with Sofosbuvir and Ledipasvir Accompanied by Immediate Improvement in Hemoglobin A1c
- Author
-
Atsuyuki Ikeda, Ken Takahashi, Kaori Ikeda, Nobuya Inagaki, Horoshi Seno, Hiroyuki Marusawa, Yoshihide Ueda, Hiroyuki Kokuryu, and Atsushi Takai
- Subjects
Male ,0301 basic medicine ,Ledipasvir ,medicine.medical_specialty ,Sustained Virologic Response ,Side effect ,Sofosbuvir ,Hepatitis C virus ,Population ,Pilot Projects ,Hepacivirus ,medicine.disease_cause ,Antiviral Agents ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,education ,Adverse effect ,Aged ,Glycated Hemoglobin ,Fluorenes ,education.field_of_study ,business.industry ,Ribavirin ,Hepatitis C ,Middle Aged ,medicine.disease ,030104 developmental biology ,chemistry ,Benzimidazoles ,Female ,030211 gastroenterology & hepatology ,Uridine Monophosphate ,business ,medicine.drug - Abstract
Background/Aims: Direct-acting antiviral agents (DAAs) have increased the sustained viral response rate with minimal adverse effects and short treatment duration. In addition, recent data suggest the possibility that hepatitis C virus (HCV) clearance results in rapid improvement in metabolic pathways. The aim of the present study was to evaluate whether the DAA treatment without ribavirin lowers hemoglobin A1c (HbA1c) at 12 weeks after therapy completion. Methods: We performed an observational study to assess the effect of sofosbuvir and ledipasvir (SOF/LED) treatment on glycemic control. We compared HbA1c levels before and after treatment with SOF/LED, considering that anemia is not a side effect of these drugs. Results: In the 36 patients with HCV eradication, HbA1c levels decreased significantly after treatment (pre-treatment 5.85% vs. post-treatment 5.65%, p < 0.01). Conclusion: This pilot study shows the possibility that HCV eradication by SOF/LED was accompanied by an improvement of glucose metabolism in the population with or without diabetes, and suggests further investigation.
- Published
- 2017
35. Utility of ultrasound-guided liver tumor biopsy for next-generation sequencing-based clinical sequencing
- Author
-
Tadayuki Kou, Hiroshi Seno, Haruhiko Takeda, Fumiyasu Nakamura, Manabu Muto, Soichi Arasawa, Masashi Kanai, Young Hak Kim, Eriko Iguchi, Hiroki Nagai, Shigemi Matsumoto, Masako Mishima, Yuji Eso, Atsushi Takai, Ken Takahashi, and Yoshihide Ueda
- Subjects
Oncology ,medicine.medical_specialty ,Liver tumor ,Hepatology ,medicine.diagnostic_test ,business.industry ,Precision medicine ,medicine.disease ,DNA sequencing ,Ultrasound guided ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,030220 oncology & carcinogenesis ,Liver biopsy ,Internal medicine ,Biopsy ,medicine ,Ultrasound-Guided Biopsy ,030211 gastroenterology & hepatology ,Multiplex ,business - Abstract
AIM Recent advances in next-generation sequencing (NGS) technologies allow for evaluation of genetic alterations in various cancer-related genes in daily clinical practice. Archival formalin-fixed paraffin-embedded (FFPE) tumor tissue is often used for NGS-based clinical sequencing assays; however, the success rate of NGS assays using archival FFPE tumor tissue is reported to be lower than that using fresh tumor tissue. We aimed to evaluate the feasibility and safety of ultrasound (US)-guided liver tumor biopsy for NGS-based multiplex gene assays. METHODS We compared the success rate of NGS assays between archival FFPE tumor tissues and US-guided liver tumor biopsy tissues, and summarized the treatment progress of the patients. RESULTS Next-generation sequencing assays using US-guided liver biopsy samples were successful in all patients (22/22), whereas the success rate with archival FFPE tumor tissue was 84.8% (151/178, P
- Published
- 2018
36. Successful endoscopic removal of fractured guidewire fragments from a peripheral bile duct using a biliary stent delivery system and biopsy forceps
- Author
-
Yuzo Kodama, Hiroshi Seno, Norimitsu Uza, Yuki Yamauchi, Akihisa Fukuda, Yoshihiro Nishikawa, and Yoshihide Ueda
- Subjects
Male ,medicine.medical_specialty ,Cholangitis ,03 medical and health sciences ,0302 clinical medicine ,Cholangiography ,Medicine ,Humans ,Cholangiopancreatography, Endoscopic Retrograde ,medicine.diagnostic_test ,business.industry ,Bile duct ,Gastroenterology ,Middle Aged ,Foreign Bodies ,Peripheral ,Surgery ,Equipment failure ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Biliary stent ,030211 gastroenterology & hepatology ,Equipment Failure ,Delivery system ,Bile Ducts ,business ,Biopsy forceps - Published
- 2018
37. The use of hepatitis B immunoglobulin with or without hepatitis B vaccine to prevent de novo hepatitis B in pediatric recipients of anti-HBc-positive livers
- Author
-
Hiroshi Seno, Atsushi Yoshizawa, Toshimi Kaido, Hiroyuki Marusawa, Yoshihide Ueda, Noriyo Yamashiki, Hideaki Okajima, and Shinji Uemoto
- Subjects
Male ,medicine.medical_specialty ,HBsAg ,Hepatitis B vaccine ,Adolescent ,Immunoglobulins ,Kaplan-Meier Estimate ,030230 surgery ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Postoperative Complications ,Internal medicine ,Living Donors ,Medicine ,Humans ,Immunologic Factors ,Hepatitis B Vaccines ,Seroconversion ,Hepatitis B Antibodies ,Child ,Retrospective Studies ,Transplantation ,business.industry ,Incidence (epidemiology) ,Incidence ,virus diseases ,Infant ,Hepatitis B ,medicine.disease ,Hepatitis B immunoglobulin ,Combined Modality Therapy ,digestive system diseases ,Liver Transplantation ,Vaccination ,Treatment Outcome ,Hepatitis b vaccination ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,030211 gastroenterology & hepatology ,Female ,business ,Follow-Up Studies - Abstract
Prophylactic measures are used to reduce DNHB after HBsAg-negative patients receive anti-HBc-positive liver grafts. This study investigated the incidence of DNHB and clinical outcomes in pediatric LT recipients under HBIG prophylaxis, with or without hepatitis B vaccination. Between 1995 and 2013, 51 HBsAg-negative pediatric recipients underwent living-donor LT from anti-HBc-positive donors. The median (range) age was 4 (0.1-17) years, 23 (45%) were male, and 71% were negative for both anti-HBc and anti-HBc. During a median follow-up of 12.1 (0.06-19.9) years, 13 (25.4%) developed DNHB; 7 of the 13 achieved HBsAg seroconversion after administration of LAM or ETV. Among studied patients, 20 (39%) received hepatitis B vaccination, and 2 of them (10%) developed DNHB. At last follow-up, 41% (21/51) discontinued HBIG either after successful HBV vaccination (n = 17) or retransplantation with anti-HBc-negative grafts (n = 4). In conclusion, pediatric LT recipients of anti-HBc-positive grafts, most of them were naive to HBV infection, were at high risk of DNHB, and consistent monitoring for the early detection of DNHB was necessary. A combination use of post-LT vaccination is promising prophylactic strategy against DNHB.
- Published
- 2018
38. Ultrasound-guided microfoam sclerotherapy with polidocanol for symptomatic giant hepatic cyst: Initial experience
- Author
-
Yuji, Eso, Akihiro, Furuta, Atsushi, Takai, Ken, Takahashi, Yoshihide, Ueda, Hiroyuki, Marusawa, and Hiroshi, Seno
- Abstract
In cases of symptomatic giant hepatic cysts, appropriate treatment is required to relieve symptoms. Ethanol, minocycline hydrochloride, and ethanolamine oleate have been conventionally used for ultrasound (US)-guided sclerotherapy. However, liquid sclerosing agents could mix with the residual fluid in the cyst and reduce their sclerotic effects. We carried out US-guided microfoam sclerotherapy using polidocanol for three patients and evaluated its efficacy and safety.Between May 2016 and March 2017, three female patients with symptomatic giant hepatic cysts were referred to our hospital. All of them were prospectively included in this study.The maximum diameters of the hepatic cysts in the three patients were 92 × 89 × 86 mm, 155 × 119 × 140 mm, and 223 × 195 × 123 mm, respectively. Polidocanol microfoam was successfully administered through an 8.5-Fr pigtail catheter for all patients. One, two, and three microfoam sclerotherapy sessions were undertaken according to the initial cyst volume for cases 1, 2, and 3, respectively. The mean reduction rates of the cyst volume were 90.1% (85.5-98.9%) at 3 months, 96.3% (91.9-99.9%) at 6 months, and 99.5% (99.1-99.9%) at 9 months after treatment. No significant treatment-induced adverse effects were observed.Ultrasound-guided microfoam sclerotherapy using polidocanol could be an effective and safe method for the treatment of symptomatic giant liver cysts.
- Published
- 2018
39. Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts
- Author
-
Atsushi Yoshizawa, Hideaki Okajima, Hiroyuki Marusawa, Yoshihide Ueda, Tsutomu Chiba, Toshimi Kaido, Shinji Uemoto, and Noriyo Yamashiki
- Subjects
medicine.medical_specialty ,HBsAg ,medicine.medical_treatment ,030230 surgery ,Liver transplantation ,Hepatitis b surface antigen ,medicine.disease_cause ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Hepatitis B virus ,Hepatology ,biology ,business.industry ,virus diseases ,digestive system diseases ,Vaccination ,Infectious Diseases ,Hepatitis b vaccination ,Immunology ,biology.protein ,030211 gastroenterology & hepatology ,Antibody ,business - Abstract
Aim Hepatitis B virus (HBV) reactivation after liver transplantation in HBV patients, or in HBV negative recipients of anti-hepatitis B core (HBc) positive grafts, has been prevented by prophylactic use of hepatitis B immunoglobulin (HBIG) and/or nucleoside/nucleotide analogs (NA). Vaccination against HBV is an alternative that may provide a chance to discontinue prophylaxis by producing anti-hepatitis B surface (HBs) antibodies. Methods We retrospectively reviewed 40 HBV positive recipients (HBV+ group) and 27 HBV negative recipients of anti-HBc positive grafts (HBV−/anti-HBc+ graft group), who were administrated double-dose hepatitis B vaccination. Recipients were regarded as responders when anti-HBs greater than 100 IU/L was maintained for 6 months or more without HBIG. Response rates of vaccine and long-term outcomes were analyzed. Results Eighteen of the 40 patients in the HBV+ group (45%) and 18 of the 27 patients in the HBV−/anti-HBc+ graft group (67%) responded to vaccination after a median of four and three times, respectively. Younger age was the only independent factor associated with vaccine response in the HBV−/anti-HBc+ graft group (P = 0.03), whereas no factor was found to be an independent predictor for vaccine response in the HBV+ group. Among the 18 responders in the HBV+ group, 17 remained without NA or HBIG 8.2 years after the start of vaccination. Ten of those required periodic booster vaccination. All 18 responders in the HBV−/anti-HBc+ graft group remained free from HBV prophylaxis 6.2 years after the start of vaccination. Conclusion Younger recipients have a greater chance to develop sufficient anti-HBs after double-dose HBV vaccination, leading to discontinue HBV prophylaxis.
- Published
- 2015
40. Slow Progression of Poorly Differentiated Gastric Carcinoma Associated with Epstein-Barr Virus Infection: 12-year Follow-up
- Author
-
Rina Yoza, Yojiro Sakuma, Yoshihide Ueda, Naoki Minami, Sachiko Minamiguchi, Ken Takahashi, Hironori Haga, and Tsutomu Chiba
- Subjects
Male ,Epstein-Barr Virus Infections ,Herpesvirus 4, Human ,medicine.medical_specialty ,medicine.medical_treatment ,Disease ,medicine.disease_cause ,Gastroenterology ,Virus ,Metastasis ,Lesion ,Gastrectomy ,Stomach Neoplasms ,hemic and lymphatic diseases ,Internal medicine ,Gastroscopy ,Internal Medicine ,medicine ,Humans ,Pathological ,Epstein–Barr virus infection ,business.industry ,digestive, oral, and skin physiology ,Hematemesis ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Virology ,Epstein–Barr virus ,digestive system diseases ,Disease Progression ,medicine.symptom ,Tomography, X-Ray Computed ,business ,Follow-Up Studies - Abstract
Epstein-Barr virus (EBV)-associated gastric carcinoma accounts for nearly 10% of all gastric carcinomas and has distinct demographic, clinical and pathological features compared with EBV-negative gastric carcinoma. We herein report the case of a patient with EBV-associated gastric carcinoma followed up for 12 years during the natural course of the disease. The appearance of the tumor on gastroscopy and computed tomography gradually changed, and the size of the lesion increased very slowly during the 12 years, without metastasis. The present case indicates that some EBV-associated gastric carcinomas progress very slowly.
- Published
- 2015
41. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing
- Author
-
Akihiro Nasu, Hiroshi Seno, Yukitaka Yamashita, Haruhiko Takeda, Tadashi Inuzuka, Yukio Osaki, Akihiro Sekine, Makoto Umeda, Hiroyuki Marusawa, Yoshihide Ueda, and Ryo Takemura
- Subjects
0301 basic medicine ,Male ,animal structures ,Pyrrolidines ,Genotype ,Hepatitis C virus ,Hepacivirus ,Drug resistance ,Viral Nonstructural Proteins ,medicine.disease_cause ,Somatic evolution in cancer ,Antiviral Agents ,Evolutionary genetics ,Article ,03 medical and health sciences ,0302 clinical medicine ,Drug Resistance, Viral ,medicine ,Humans ,Treatment Failure ,NS5A ,Aged ,Genetics ,Sulfonamides ,Multidisciplinary ,biology ,Imidazoles ,virus diseases ,High-Throughput Nucleotide Sequencing ,Valine ,Hepatitis C ,Hepatitis C, Chronic ,medicine.disease ,biology.organism_classification ,Isoquinolines ,Virology ,digestive system diseases ,Drug Resistance, Multiple ,030104 developmental biology ,embryonic structures ,030211 gastroenterology & hepatology ,Drug Therapy, Combination ,Female ,Carbamates ,Synonymous substitution ,Viral genetics - Abstract
Resistance-associated variant (RAV) is one of the most significant clinical challenges in treating HCV-infected patients with direct-acting antivirals (DAAs). We investigated the viral dynamics in patients receiving DAAs using third-generation sequencing technology. Among 283 patients with genotype-1b HCV receiving daclatasvir + asunaprevir (DCV/ASV), 32 (11.3%) failed to achieve sustained virological response (SVR). Conventional ultra-deep sequencing of HCV genome was performed in 104 patients (32 non-SVR, 72 SVR), and detected representative RAVs in all non-SVR patients at baseline, including Y93H in 28 (87.5%). Long contiguous sequences spanning NS3 to NS5A regions of each viral clone in 12 sera from 6 representative non-SVR patients were determined by third-generation sequencing, and showed the concurrent presence of several synonymous mutations linked to resistance-associated substitutions in a subpopulation of pre-existing RAVs and dominant isolates at treatment failure. Phylogenetic analyses revealed close genetic distances between pre-existing RAVs and dominant RAVs at treatment failure. In addition, multiple drug-resistant mutations developed on pre-existing RAVs after DCV/ASV in all non-SVR cases. In conclusion, multi-drug resistant viral clones at treatment failure certainly originated from a subpopulation of pre-existing RAVs in HCV-infected patients. Those RAVs were selected for and became dominant with the acquisition of multiple resistance-associated substitutions under DAA treatment pressure.
- Published
- 2017
42. Late-onset acetaminophen-induced allergic hepatitis with progression to chronicity
- Author
-
Masataka Yokode, Masako Mishima-Iwai, Ken Takahashi, Yoshito Kimura, Yoshihide Ueda, Yugo Sawai, and Tsutomu Chiba
- Subjects
Liver injury ,Hepatitis ,Idiosyncrasy ,Hepatology ,business.industry ,organic chemicals ,digestive, oral, and skin physiology ,Analgesic ,Late onset ,medicine.disease ,digestive system ,Acetaminophen ,stomatognathic diseases ,Infectious Diseases ,Immunology ,medicine ,Allergic hepatitis ,Antipyretic ,business ,medicine.drug - Abstract
Acetaminophen (paracetamol), a widely used antipyretic/analgesic, is a well-known agent causing acute hepatic injury. Whereas most cases are caused by its intrinsic hepatotoxicity, idiosyncratic hepatitis by the allergic mechanism is extremely rare. We herein report a case of late-onset acetaminophen-induced allergic hepatitis with progression to chronicity. This unique case extends the spectrum of acetaminophen-induced liver injury. Clinicians should be aware of this unusual clinical manifestation. The mechanism underlying the immunological reaction to acetaminophen remains to be elucidated.
- Published
- 2014
43. Significance of pretransplant abstinence on harmful alcohol relapse after liver transplantation for alcoholic cirrhosis in Japan
- Author
-
Takahito Yagi, Takafumi Ichida, Naoki Kawagishi, Hiroyuki Kimura, Yoshihide Ueda, and Hiroto Egawa
- Subjects
medicine.medical_specialty ,Alcoholic liver disease ,Cirrhosis ,Hepatology ,Recidivism ,business.industry ,media_common.quotation_subject ,medicine.medical_treatment ,Incidence (epidemiology) ,Alcohol ,Abstinence ,Liver transplantation ,medicine.disease ,Surgery ,chemistry.chemical_compound ,Infectious Diseases ,chemistry ,Internal medicine ,Cohort ,medicine ,business ,media_common - Abstract
Aim Alcoholic liver cirrhosis (ALC) is an established indication for liver transplantation (LT). Although the importance of preoperative abstinence is accepted, the optimal period of pretransplant abstinence is unclear. Our previous report in a Japanese cohort revealed a significant negative impact of recidivism on patient survival but failed to show significance of the length of pretransplant abstinence. The aim of this study was to evaluate the optimal period of pretransplant abstinence. Methods Subjects underwent LT for ALC (n = 195: 187 living donor liver transplantations, five deceased donor liver transplantations and three domino LT) in Japan from November 1997 to December 2011. Risk factors and the impact on outcome of alcohol relapse were analyzed in 140 patients, after excluding 26 patients with in-hospital mortality and 29 patients without information about alcohol relapse. Results The incidence of alcohol consumption after LT was 22.9% (32/140). The relapse time was within 18 months after LT in 24 patients, after 18 months in two patients and unknown in six patients. Alcohol-related damage occurred in 18 of the 24 patients with recidivism within 18 months. The patient survival rate of patients with harmful relapse was significantly lower than that of abstinent patients and patients with non-harmful relapse (P = 0.019). Preoperative abstinence shorter than 18 months was a significant indicator of the risk of harmful relapse (P = 0.009). High-risk alcohol relapse scores had no impact on the incidence. Conclusion Preoperative abstinence was an important predictor of post-transplant harmful relapse leading to inferior outcomes.
- Published
- 2014
44. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience
- Author
-
Nobuhisa Akamatsu, Hideaki Okajima, Tomoharu Yoshizumi, Akinobu Taketomi, Akihiko Soyama, Norihiro Kokudo, Yuko Kitagawa, Shinji Uemoto, Yoshihiko Maehara, Ryoichi Goto, Toru Ikegami, Masahiro Shinoda, Susumu Eguchi, and Yoshihide Ueda
- Subjects
Ledipasvir ,Male ,medicine.medical_specialty ,Sofosbuvir ,Genotype ,Sustained Virologic Response ,Pleural effusion ,medicine.medical_treatment ,Hepacivirus ,Liver transplantation ,Viral Nonstructural Proteins ,Gastroenterology ,Antiviral Agents ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Japan ,Recurrence ,Internal medicine ,Drug Resistance, Viral ,Ribavirin ,medicine ,Living Donors ,Humans ,Postoperative Period ,Adverse effect ,Aged ,Fluorenes ,business.industry ,Hepatitis C ,Hepatology ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,Virology ,Liver Transplantation ,chemistry ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Benzimidazoles ,Drug Therapy, Combination ,Female ,business ,medicine.drug - Abstract
The optimal therapy for recurrent hepatitis C virus (HCV) infection after liver transplantation has not yet been established. This study aimed to clarify the efficacy and safety of interferon-free therapy with sofosbuvir and ledipasvir without ribavirin for 12 weeks in Japanese patients with HCV genotype 1b infection after living donor liver transplantation. A cohort study of living donor liver transplant recipients with recurrent HCV genotype 1b infection treated with sofosbuvir (400 mg/day) and ledipasvir (90 mg/day) was performed at six liver transplant centers in Japan. Fifty-four patients were treated with sofosbuvir and ledipasvir. Thirty-eight patients (70%) were treatment experienced, including 17 patients who had undergone prior direct-acting-antiviral-based triple therapy. Ten patients had resistance-associated substitutions at L31 or Y93 in the NS5A region of the HCV genome. Fifty-three patients completed the 12-week treatment protocol; treatment was discontinued in one patient who developed pneumonia at 4 weeks and died thereafter. All 53 patients who completed the treatment regimen achieved a sustained virological response 12 weeks after completion of treatment. Treatment was well tolerated in most patients, but seven patients developed serious adverse events, including hemorrhagic duodenal ulcers (n = 3), infection (n = 2), pleural effusion (n = 1), and alveolar hemorrhage (n = 1). Sofosbuvir and ledipasvir treatment without ribavirin for 12 weeks was highly effective in achieving a sustained virological response in Japanese patients who developed recurrent HCV genotype 1b infection after living donor liver transplantation.
- Published
- 2016
45. 957 – The Long-Term Consequences of the Donors After Living Donor Liver Transplantation; Predictors and Clinical Impact of Splenic Enlargement and Incomplete Liver Restoration
- Author
-
Noriyo Yamashiki, Tomoko Ishibashi, Yasuko Kojitani, Yumi Umeya, Kojiro Taura, Yusuke Kimura, Takashi Ito, Shinji Uemoto, Koichiro Hata, Yoshinobu Ikeno, Toshimi Kaido, Nguyen Hai Nam, Yoshihide Ueda, Shintaro Yagi, Yusuke Uemoto, Ken Fukumitsu, Naoko Kamo, and Kenji Yoshino
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,Medicine ,Living donor liver transplantation ,business ,Term (time) ,Surgery - Published
- 2019
46. Utility of Sonazoid-enhanced ultrasound-guided liver tumor biopsy for next-generation sequencing-based clinical sequencing
- Author
-
Hiroshi Seno, Yoshihide Ueda, Ken Takahashi, Atsushi Takai, and Yuji Eso
- Subjects
Pathology ,medicine.medical_specialty ,Liver tumor ,Acoustics and Ultrasonics ,Radiological and Ultrasound Technology ,medicine.diagnostic_test ,business.industry ,Ultrasound ,Biophysics ,medicine.disease ,Ultrasound guided ,DNA sequencing ,Clinical Practice ,Liver biopsy ,Biopsy ,Medicine ,Radiology, Nuclear Medicine and imaging ,Multiplex ,business - Abstract
Introduction Recent advances in next-generation sequencing (NGS) technologies allow for evaluation of genetic alterations in various cancer-related genes in daily clinical practice. Archival formalin-fixed paraffin-embedded (FFPE) tumor tissue is often used for NGS-based clinical sequencing assays; however, the success rate of NGS assays using archival FFPE tumor tissue is reported to be lower than that using fresh tumor tissue. We aimed to evaluate the feasibility and safety of Sonazoid-enhanced ultrasound (SEUS)-guided liver tumor biopsy for NGS-based multiplex gene assays. Methods We compared the success rate of NGS assays between archival FFPE tumor tissues and SEUS-guided liver tumor biopsy tissues, and summarized the treatment progresses of the patients. Results NGS assays using SEUS-guided liver biopsy samples were successful in all patients (22/22), whereas the success rate with archival FFPE tumor tissue was 84.8% (151/178, p Conclusion Our findings suggest that SEUS-guided liver tumor biopsy is a useful and safe method for obtaining high-quality samples for NGS-based clinical sequencing. In cases with metastatic liver tumors, SEUS-guided biopsy should be considered to provide accurate and optimal sequencing results for patients.
- Published
- 2019
47. Sonazoid-enhanced ultrasound for predicting therapeutic effect of lenvatinib against hepatocellular carcinoma
- Author
-
Hiroshi Seno, Atsushi Takai, Ken Takahashi, Yoshihide Ueda, and Yuji Eso
- Subjects
Oncology ,medicine.medical_specialty ,Treatment response ,Acoustics and Ultrasonics ,Radiological and Ultrasound Technology ,medicine.drug_class ,Angiogenesis ,business.industry ,Therapeutic effect ,Ultrasound ,Biophysics ,medicine.disease ,Tyrosine-kinase inhibitor ,chemistry.chemical_compound ,chemistry ,Hepatocellular carcinoma ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,Time intensity curve ,business ,Lenvatinib - Abstract
Introduction Recently, a multi-targeted tyrosine kinase inhibitor, lenvatinib, was approved as first-line therapy for unresectable hepatocellular carcinoma (HCC). Lenvatinib exerts antitumor activity by inhibiting angiogenesis through blockage of the VEGF and FGF pathway. Contrast-enhanced CT (CECT) is generally used for evaluation of therapeutic effect of lenvatinib; however, CECT is unsuitable for frequent monitoring. We aimed to evaluate the feasibility of Sonazoid-enhanced ultrasound (SEUS) for predicting therapeutic effect of lenvatinib. Methods Among patients with HCC who started treatment with lenvatinib in hour hospital, five cases who could receive time intensity curve (TIC) analysis by SEUS using LOGIQ E9 (GE Healthcare) were enrolled in this study. We compared the results of TIC analysis within 1 month after treatment initiation and first CECT after 2-3 months. Results The reduction rate of tumor blood flow by SEUS-TIC analysis within 1 month after treatment initiation and the evaluation of treatment response by first CECT after 2-3 months showed high correlation. However, SEUS-TIC analysis was applicable to limited cases who have a hypervascular nodule that can be visualized and measured stably with US and can stably hold breath. Conclusion Our findings suggest the utility of TIC analysis by SEUS for predicting therapeutic effect of lenvatinib against HCC in appropriate cases.
- Published
- 2019
48. Plasma cell hepatitis induced by the termination of antiviral therapy for recurrent hepatitis C after living donor liver transplantation
- Author
-
Shinji Uemoto, Hironori Haga, Aya Miyagawa-Hayashino, Tsutomu Chiba, Atsushi Yoshizawa, Yasuhiro Ogura, and Yoshihide Ueda
- Subjects
Hepatitis ,Hepatology ,business.industry ,Ribavirin ,medicine.medical_treatment ,Hepatitis C ,Liver transplantation ,Plasma cell ,medicine.disease ,chemistry.chemical_compound ,Infectious Diseases ,medicine.anatomical_structure ,Immune system ,chemistry ,Pegylated interferon ,Interferon ,Immunology ,medicine ,business ,medicine.drug - Abstract
Plasma cell hepatitis (PCH) is an idiopathic disorder characterized by plasma cell infiltration in the allografts of patients who have undergone liver transplantation. Although an increasing number of cases of PCH have been reported in liver transplant recipients with hepatitis C recurrence treated with interferon, it is unclear whether PCH is induced by interferon itself. Here, we describe the cases of two patients who developed PCH just after the termination of antiviral therapy for recurrent hepatitis C after living donor liver transplantation. Liver dysfunction appeared at 1 month in one patient and 2 months in the other patient after pegylated interferon plus ribavirin therapy, and liver histology showed interface hepatitis with plasma cell-rich lymphoid aggregates. Both patients recovered after steroid therapy and achieved sustained virological response. These cases suggest that PCH could be induced by the alteration of the immune condition resulting from the termination of antiviral therapy. PCH should be considered when the transaminase levels increase after antiviral therapy, and it should be carefully distinguished from hepatitis C relapse.
- Published
- 2013
49. Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C
- Author
-
Yoshihide Ueda, Shigeru Ohtsuru, Shinji Uemoto, Etsuro Hatano, and Toshimi Kaido
- Subjects
medicine.medical_specialty ,Daclatasvir ,Hepatology ,business.industry ,medicine.medical_treatment ,Hepatitis C ,Liver transplantation ,medicine.disease ,Gastroenterology ,Tacrolimus ,chemistry.chemical_compound ,Infectious Diseases ,chemistry ,Hepatitis C Virus Positive ,Interferon ,Internal medicine ,Immunology ,Medicine ,Asunaprevir ,Liver function ,business ,medicine.drug - Abstract
Severe cholestatic hepatitis C (SCH) is a unique variant of recurrent hepatitis C that occurs after liver transplantation. Unfortunately, the prognosis of SCH is poor, and interferon (IFN) therapy has been reported to not improve the prognosis. We herein report a case of progressive SCH with acute cellular rejection (ACR) and bacterial infection, which was successfully treated using IFN-free therapy with daclatasvir and asunaprevir. A 43-year-old man was diagnosed with SCH and mild ACR at day 48 after liver transplantation, and IFN-free therapy with daclatasvir and asunaprevir was started. Although he experienced catheter-related bacteremia on the first day, the IFN-free therapy was safely continued, which immediately caused his liver function to improve. His bilirubin levels decreased from 11.1 to 2.1 mg/dL and serum hepatitis C virus RNA levels became undetectable after 4 weeks of the treatment. This case indicates that IFN-free therapy for progressive SCH with acute cellular rejection and bacterial infection is safe and effective, and may improve the outcomes of hepatitis C virus positive transplant recipients.
- Published
- 2015
50. Sonazoid-enhanced ultrasonography guidance improves the quality of pathological diagnosis in the biopsy of focal hepatic lesions
- Author
-
Ken Takahashi, Hiroshi Seno, Haruhiko Takeda, Tadashi Inuzuka, Hiroyuki Marusawa, Yoshihide Ueda, Minami Lee, Atsushi Takai, Tomonori Matsumoto, and Yuji Eso
- Subjects
Adult ,Image-Guided Biopsy ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Iron ,Liver Abscess ,Contrast Media ,Malignancy ,Ferric Compounds ,030218 nuclear medicine & medical imaging ,Cholangiocarcinoma ,03 medical and health sciences ,0302 clinical medicine ,Biopsy ,medicine ,Carcinoma ,Humans ,Pathological ,Aged ,Retrospective Studies ,Ultrasonography ,Aged, 80 and over ,Hepatology ,medicine.diagnostic_test ,business.industry ,Biopsy, Needle ,Liver Neoplasms ,Gastroenterology ,Retrospective cohort study ,Oxides ,Middle Aged ,medicine.disease ,Hepatic malignancy ,Molecular analysis ,Bile Duct Neoplasms ,Liver ,Focal Nodular Hyperplasia ,030211 gastroenterology & hepatology ,Female ,Radiology ,business - Abstract
BACKGROUND/AIM Contrast-enhanced ultrasonography (US) has improved the detection and characterization of focal hepatic lesions. Recently, the importance of obtaining high-quality samples in the biopsy of hepatic lesions has been increasing not only in the field of pathological diagnosis but also in molecular analysis for predicting the effectiveness of anticancer agents and molecular targeted drugs. We evaluated the utility of Sonazoid-enhanced ultrasonography (SEUS) in guiding percutaneous biopsy of focal hepatic lesions by comparing the results of histopathological diagnosis between B-mode US and SEUS guidance. METHODS AND MATERIALS This retrospective study examined 121 focal hepatic lesions in 108 patients (mean age: 63.8 years) referred for US-guided percutaneous biopsy. The technical success rate was defined as the percentage of the lesions diagnosed clearly at the initial biopsy. RESULTS Among 121 lesions, 56 lesions were subjected to biopsy with B-mode US guidance whereas 65 were subjected to SEUS guidance. The technical success rate was significantly higher under SEUS guidance than under B-mode US guidance (92.3 vs. 76.8%, respectively, P
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.